Drools Telpet Telmisartan Veterinary ARB Oral Suspension for Dogs & Cats | Hypertension, Chronic Kidney Disease (CKD) & Proteinuria Management | 30ml | Veterinary Prescription

Prescription Required — For veterinary use only. Administer strictly under the supervision of a licensed veterinarian. Do not adjust dose without veterinary guidance. Monitor blood pressure and renal parameters as directed by your veterinarian during therapy.

Drools Telpet Telmisartan Veterinary ARB Oral Suspension for Dogs & Cats (30ml)

Drools Telpet is a veterinary prescription oral suspension containing Telmisartan, a selective Angiotensin II Type 1 (AT1) receptor blocker (ARB), formulated for the management of systemic hypertension and chronic kidney disease (CKD)-associated proteinuria in dogs and cats. Telmisartan is the ARB of choice in feline veterinary medicine, licensed for reduction of proteinuria in cats with chronic kidney disease (IRIS CKD Stages 1–4). Also indicated for systemic hypertension in both dogs and cats. The oral suspension format (30ml bottle) enables accurate weight-based dosing, making it suitable for cats and small dogs where tablet dosing precision is limited.

Composition (per ml — confirm from product label)

• Telmisartan: Concentration per ml — confirm from physical Drools Telpet product label
• Suspension vehicle and excipients — confirm from label; shake well before use

Mechanism of Action

• Telmisartan selectively blocks Angiotensin II Type 1 (AT1) receptors, preventing Angiotensin II from binding and activating the renin-angiotensin-aldosterone system (RAAS)
• AT1 blockade causes vasodilation, reduces systemic vascular resistance, and lowers systemic blood pressure
• Reduces intraglomerular pressure and proteinuria in CKD by blocking Angiotensin II-mediated efferent arteriolar vasoconstriction in the glomerulus — the primary mechanism for its renoprotective effect in feline CKD
• Unlike ACE inhibitors, ARBs block AT1 receptors directly without affecting bradykinin — lower risk of cough or bradykinin-mediated side effects

Therapeutic Class

• Veterinary selective Angiotensin II Type 1 (AT1) receptor blocker (ARB) prescription oral suspension for dogs and cats — systemic hypertension and CKD proteinuria management

Indications

• Cats — CKD proteinuria reduction: Reduction of proteinuria in cats with chronic kidney disease (CKD), IRIS Stages 1–4; primary indication; Telmisartan is the preferred ARB for feline CKD management
• Cats — systemic hypertension: Management of systemic hypertension (blood pressure ≥160 mmHg) in cats, including CKD-associated and idiopathic hypertension
• Dogs — systemic hypertension: Management of systemic hypertension in dogs associated with CKD, hyperadrenocorticism, diabetes mellitus, or other causes
• Dogs — CKD: Adjunct renoprotective therapy for reduction of glomerular hypertension and proteinuria in dogs with CKD and proteinuria (UPC > 0.5)

Directions for Use

• Shake well before each use
• Administer orally as directed by a licensed veterinarian — typically once daily; confirm dose and frequency from prescription
• Typical veterinary dose: cats — 1.5 mg/kg PO once daily (CKD/hypertension); dogs — 0.5–1 mg/kg PO once daily; confirm exact dose from veterinary prescription
• Use the supplied dosing syringe for accurate measurement; do not estimate dose
• Can be administered directly into the mouth or mixed with a small amount of food
• Store as directed on label; confirm if refrigeration is required after opening

Safety Information

• Prescription medicine — for veterinary use only; administer under licensed veterinary supervision with confirmed diagnosis and baseline blood pressure/renal parameters
• Monitor blood pressure and renal function (creatinine, BUN, UPC ratio) regularly during therapy — AT1 blockade can reduce GFR in patients with severe pre-existing renal compromise; consult veterinarian if deterioration observed
• Hypotension risk — do not use concurrently with other antihypertensives (amlodipine, ACE inhibitors) without veterinary assessment of combined blood pressure-lowering effects
• Hyperkalaemia — RAAS blockade can increase serum potassium; monitor electrolytes in patients on potassium-sparing diuretics or potassium supplementation
• Not for use in pregnant or breeding animals — RAAS blockade has known teratogenic and foetotoxic effects in mammals
• Keep out of reach of children; store as directed on label